Company intelligence / Profile preview

Orange Gateway

Durham, North Carolina, United Statesorangegateway.com ↗

Ownership: Private
Development stage: Other

Overview

Gateway Biotechnology is developing first-in-class drug therapies for tinnitus and hearing disorders. Its lead programs include a nasal small molecule formulation (GW-TT2) for recent onset tinnitus and a gene therapy candidate (GW-TT5) for severe debilitating tinnitus. Both are currently in preclinical development, with promising efficacy shown in animal models. There are no FDA-approved drugs for tinnitus to date.

Therapeutic areas: Neurology
Modalities: Small moleculeGene therapyBiological products
Industry: Biotech

Partnerships

Not specifically listed; funding from NIH and Department of Defense grants noted.

Beyond the preview

Go deeper on Orange Gateway.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orange Gateway.

Explore the full profile